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1. Introduction
Ligands of the tumour necrosis factor (TNF) superfamily have diverse roles in the organisation
and function of the immune system. Although most TNF family ligands are synthesised as type
II transmembrane proteins, many are processed subsequently into soluble forms by limited
proteolysis(Bodmer et al., 2002). For some ligands, conversion to the soluble form is essential
for biological activity, for example a mutation in the proteolysis motif of ectodysplasin (EDA)
is associated with the genetic disorder X-linked hypohidrotic ectodermal dysplasia (XLHED)
(Schneider et al., 2001;Chen et al., 2001). In contrast, the cytotoxic activity of FasL (CD95L)
is reduced significantly upon cleavage(Tanaka et al., 1998;Shudo et al., 2001) and soluble
FasL antagonises killing mediated by membrane bound FasL(Suda et al., 1997). The biological
activity of the ligand can be restored by artificially increasing the avidity of the ligand(Holler
et al., 2003), suggesting that it is not the solubilisation of the ligand per se that removes the
bioactivity but rather its inability to cross-link its cognate receptor. TNF family ligands exist
as trimers, both in membrane bound and soluble forms and the engagement of the trimeric
ligand with a trimeric signalling competent receptor may be a prerequisite for a secondary
multimerisation event and the formation of supramolecular signalling clusters(Siegel et al.,
2004;Henkler et al., 2005).
The initial event in the process of viral entry into a target cell is the interaction between the
virus and its cellular receptor and the specificity of this interaction determines both viral cell
tropism and pathogenicity. The primary receptor for the feline immunodeficiency virus (FIV)
is CD134 (OX40), a member of the TNF receptor (TNFR) superfamily and co-stimulatory
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molecule with a crucial role in the expansion and survival of T cells that have encountered
antigen(Gramaglia et al., 1998;Pippig et al., 1999;Kopf et al., 1999). As both CD134(Taylor
and Schwarz, 2001) and its ligand CD134L (OX40L, CD252)(Wang et al., 2006) exist in
membrane bound and soluble forms in vivo, the process of FIV infection, and ultimately disease
pathogenesis, may be sensitive to modulation by soluble receptor and ligand produced
endogenously. Further, it may be possible to block the virus-receptor interaction using soluble
forms of receptor or ligand administered as therapeutics. Soluble feline CD134 has been
produced as an N-terminal immunoglobulin Fc region-fusion protein (sFc-CD134) and used
to study the virus-receptor interaction(de Parseval et al., 2006;de Parseval et al., 2004a;de
Parseval et al., 2004b;Willett et al., 2007;Willett et al., 2006a). However, when feline CD134L
was prepared in soluble forms analogous to the widely used sFc- and FLAG-tagged forms of
human and murine CD134L, the ligand exhibited no receptor-binding activity. Similar
observations have been made with the related TNF superfamily ligands FasL and TRAIL(Berg
et al., 2007) where the soluble murine ligands were completely devoid of Fas and TRAILR2
binding activity respectively, while human FasL or TRAIL prepared under identical conditions
bound well to Fas and TRAILR2 respectively. Given that soluble murine CD134L displayed
inhibitory activity against FIV(Willett et al., 2007), CD134L may prove a useful tool for the
further dissection of the FIV-receptor interaction and its role in viral pathogenesis. In this study,
we set out to reconstitute a functional soluble feline CD134L. We demonstrate that enforced
trimerisation of feline CD134L via the introduction of a subdomain of the tenascin-C (TNC)
oligomerization domain is sufficient to restore full ligand-binding activity. The resulting fusion
protein is as effective as anti-CD134 monoclonal antibody at detecting CD134 expression and
displays strain-specific blocking of viral entry.
2. Materials and Methods
2.1. Cells and viruses
MYA-1(Miyazawa et al., 1989), MCC(Cheney et al., 1990), CLL(Willett et al., 2006b) and
NSO cell lines were cultured in RPMI 1640 medium supplemented with 10% foetal bovine
serum (FBS), 2mM glutamine, 0.11mg/ml sodium pyruvate 100 IU/ml penicillin and 100 μg/
ml streptomycin (complete RPMI). 293T and NP2 cells were maintained in Dulbecco’s
modification of Eagle’s medium (DMEM) supplemented as above. The medium for MYA-1
cells was supplemented with conditioned medium from a murine cell line (L2.3, kindly
provided by M. Hattori and T. Miyazawa) transfected with a human IL-2 expression construct
(equivalent to 100 U/ml of recombinant human IL-2) and 50μM 2-mercaptoethanol. All media
and supplements were obtained from InVitrogen Life Technologies Ltd. (Paisley, UK). Stable
cell lines expressing constructs based on the pDONAI (Takara) or PCR3 (InVitrogen)
expression vectors were maintained in G418-supplemented media (InVitrogen, Paisley, UK)
while those based on pTorsten(Spiller et al., 2003) were maintained in hygromycin-
supplemented media as previous(Willett et al., 2007). Chimeric viruses derived from the GL8
molecular were prepared by transfection of the molecular clone into 293T cells followed by
passage of the 0.45μm-filtered supernatant onto MYA-1 cells. The infected cells were cultured
until cytopathicity was evident (normally ~1 to 2 weeks) at which time the supernatant was
clarified by centrifugation, 0.45μm-filtered and stored at −80°C.
2.2. Antibodies and flow cytometry
Anti-feline CD134 has been described previously(Willett et al., 2007). Fluorescein
isothiocyanate (FITC)-conjugated anti-feline CD134 was obtained from AbD Serotec, Oxford,
UK. Anti-human CD134 (BerACT35) was obtained from Alexis Biochemicals (Axxora (UK)
Ltd., Nottingham), anti-mouse B220 (CD45R) was from BD Biosciences (Pharmingen,
Oxford, United Kingdom), while anti-human CXCR4 (#44701) was obtained from R&D
Systems, Abingdon, Oxford, United Kingdom. Cells to be processed for flow cytometry were
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resuspended in phosphate buffered saline (PBS) supplemented with 1.0% (w/v) bovine serum
albumin, 0.1% (w/v) sodium azide (PBA). Cells were incubated with 1μg of primary antibody
for 30 minutes at 4°C and then washed twice with PBA by centrifugation at 1000 rpm for 5
minutes. Bound primary antibody was detected with the appropriate anti-mouse IgG secondary
antibody (Serotec, Oxford, United Kingdom) corresponding to the isotype of the primary
antibody and conjugated to either fluorescein isothiocyanate (FITC) or R-phycoerythrin (PE).
Cells were incubated with secondary antibody for 30 minutes at 4°C and then washed twice
with PBA by centrifugation at 1000rpm for 5 minutes and resuspended in 1ml of PBA for
analysis. All samples were analysed on a Beckman Coulter EPICS MCS-XL flow cytometer,
10,000 events being collected for each sample in LIST mode. Analysis gates were set using
isotype-matched negative control antibodies such that <1.0% of events fell within the gate.
Data were analysed using EXPO 32 ADC Analysis (Advanced Cytometry Systems).
2.3. Production of soluble feline CD134-ligand
The cloning of a cDNA encoding feline CD134L (fCD134L) has been described previously
(Willett et al., 2007). In order to generate soluble fCD134L, the extracellular domain (aa 51–
183) of fCD134L was cloned as a PstI-EcoRI fragment into both PS261(Bossen et al., 2006)
(generating FLAG-fCD134L) and PS1297(Bossen et al., 2006) (generating Fc-fCD134L),
similar constructs bearing murine and human CD134L have been described previously(Bossen
et al., 2006). Chimeric feline x human and human x feline CD134L fusions were prepared by
exchanging PstI-SacI (aa 1–113) and SacI-EcoRI (aa 114–183) fragments between feline and
human CD34L in the PS261 vector (although only the fCD134L cDNA has an internal SacI,
a similar site was introduced into hCD134L by PCR-directed mutagenesis using the
oligonucleotide 5′-AATGTTGAGCTCCTGGGAGAAGTAGCCCTT-3′). The trimerisation
domain of murine ACRP30 (aa 18–111) was introduced into the expression vector for FLAG-
tagged murine and feline ligands(Bossen et al., 2006) as an NsiI-PstI fragment. The
trimerisation domain of chicken tenascin (aa 110–139)(Berg et al., 2007) was introduced into
the expression vectors for the FLAG and Fc-tagged ligands(Bossen et al., 2006) as an NsiI-
PstI fragment. The resulting Fc-tagged vectors encode the hemagglutinin signal peptide, the
hinge and Fc domain of human IgG1 (excluding the Stop codon, aa 104–330 of
GenBank:P01857), a linker with sequence RSPQPQPKPQPKPEPEGSLH, aa 110–139 of
chicken tenascin-C, a linker with sequence GTGGGSGGRGLQ, and the TNF homology
domain of CD134L (aa 52–183 of human CD134L, aa 51–198 of mouse CD134L or aa 52–
183 of feline CD134L). The expression vector for FLAG-tagged ligands encodes the
hemagglutinin signal peptide, the FLAG sequence (DYKDDDDKG), a linker with sequence
GPGQVQLH, aa 110–139 of chicken tenascin-C, a linker with sequence GTGGGSGGRGLQ,
and the TNF homology domain of feline OX40L (aa 52–183).
Soluble ligands were prepared by transient transfection of 293T cells with expression vector
using SuperFect, QIAgen (Crawley, UK) and culturing in OptiMEM (InVitrogen) for 72 hours.
Supernatants were collected, filtered at 0.45μm, concentrated 10-fold using an Amicon Ultra
centrifugal filter (Ultracel 10K, Millipore Corporation, Billerica, MA, USA) and stored at −80°
C prior to use.
2.4. Preparation of HIV (FIV) pseudotypes
FIV env gene expression constructs GL8, B2542, CPG41 and PPR have been described
previously(Shimojima et al., 2004;Willett et al., 2006b;Willett et al., 2006a). 5μg of each
VR1012-env and 7.5μg of pNL4-3-Luc-E−R− were co-transfected into HEK-293T cells using
SuperFect activated dendrimer (QIAgen) as per manufacturer’s instructions. The nomenclature
“HIV(FIV)” denotes an FIV Env protein on an HIV particle. Culture supernatants were
collected at 48 hours post-transfection, filtered at 0.45μm and frozen at −80°C until required.
Target cell lines were seeded at 5×104 cells per well of a CulturPlate™-96 assay plate (Perkin
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Elmer, Life and Analytical Sciences, Beaconsfield, UK) and used immediately. The cells were
then infected with 50μl of HIV (FIV) luciferase pseudotypes, cultured for 72 hours and then
luciferase activity quantified by the addition of 50μl of Steadylite HTS™ (Perkin Elmer)
luciferase substrate prior to measurement by single photon counting on a MicroBeta TriLux
luminometer (Perkin Elmer).
2.5. Large scale production of recombinant IgG-Fc fusion proteins
Fc-TNC-mCD134L, fCD134L and hCD134L were produced from CHO cells stably
transfected with the respective construct in CELLine AD1000 bioreactor flasks (Integra
Biosciences (Scientific Laboratory Supplies, Nottingham, U.K.)) in medium supplemented
with low IgG serum (Integra Biosciences). Culture supernatants were filtered at 0.45μm and
frozen at −80°C prior to use in order to preserve optimal bioactivity. Where appropriate, Fc-
tagged ligands were purified by affinity chromatography using protein A-Sepharose
(HiTrap™ Protein A HP, GE Healthcare, Chalfont St. Giles, U.K) and bound protein was eluted
with 0.1M glycine pH 3.0, neutralising the eluate immediately to pH 7.0 by collection into
1.5M Tris pH8.6. The integrity of the purified proteins was assessed by immunoblotting, fusion
protein being detected with goat anti-human IgG-Fc horseradish peroxidase (HRP) conjugate
(Sigma, Poole, U.K.) and visualised with amino-9-ethylcarbazole (Vectastain AEC substrate
kit, Vector Laboratories Ltd., Peterborough, U.K.).
2.6. Binding of soluble CD134Ls to CD134
MCC cells expressing feline, human or chimeric CD134s(Willett et al., 2007) were incubated
with soluble CD134Ls for 30 minutes on ice in complete RPMI supplemented with 10mM N-
(2-Hydroxyethyl) piperazine-N′-(2-ethanesulfonic acid) (HEPES). Cells were then washed
twice by centrifugation through phosphate buffered saline supplemented with 1%bovine serum
albumin and 0.1% sodium azide (PBA) at 1000rpm and incubated with i) PE-conjugated anti-
human IgG Fc (eBioscience, San Diego, USA) for 30 minutes at 4°C or ii) M2 anti-FLAG
(Sigma, Poole, Dorset, U.K.) for 30 minutes at 4°C followed by PE-anti-mouse IgG (AbD
Serotec, Oxford, U.K.). Cells were then washed twice with PBA by centrifugation at 1000rpm
for 5 minutes and resuspended in 1ml of PBA for analysis and analysed by flow cytometry as
above.
2.7. Inhibition of viral entry
1×105 MYA-1 or CLL-CD134 cells were incubated with ligand or inhibitor in complete
medium + HEPES for 30 minutes at room temperature. Viral pseudotypes were added,
incubated for a further hour before the cells were washed once by centrifugation and then plated
in 96-well culture-treated luciferase assay plates (CulturPlate™ 96) in complete medium in the
presence of maintenance ligand at a 1:4 dilution of the blocking concentration. Cultures were
maintained for 72 hours post-infection at which point glow luciferase assay substrate was added
and luminescence quantified.
The effect of the ligands on productive infection was assayed by incubating cells with ligand
at 12.5μg/ml for 30 mins followed by the addition of virus for 1 hour. Cells were then washed
twice with complete RPMI by centrifugation at 1000rpm, 5 mins. and plated into 48 well culture
plates in the presence of 1.25 μg/ml ligand. The culture wells were sampled (every 2–3 days),
the supernatants clarified by centrifugation (13.5K, 5 mins.) and stored at −80°C for reverse
transcriptase (RT) assay. RT was quantified in the thawed samples by using a non-isotopic
assay bromo-deoxyuridine-triphosphate (BrdU) incorporation test kit (Lenti RT, Cavidi AB,
Uppsala, Sweden).
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2.8. Polyacrylamide gel electrophoresis (PAGE) analyses
Approximately 1μg of affinity-purified proteins were separated using reducing and non-
reducing Laemmli sample buffer(Laemmli, 1970) on 12% polyacrylamide gels. Blue-native
electrophoresis(Schagger, 2001) used 4–16% NativePAGE™ Bis-Tris gels (Invitrogen)
according to the manufacturer’s instructions in comparison with NativeMark™ unstained
molecular weight markers (Invitrogen). Separated proteins were transferred to nitrocellulose
by electroblotting (iBlot™, Invitrogen); molecular weight markers were visualised using
Ponceau stain and bound ligands were detected using goat anti-human IgG-Fc horseradish
peroxidase (HRP) conjugate followed by visualisation with amino-9-ethylcarbazole.
3. Results
3.1. Production of soluble feline CD134L
Previous studies have demonstrated that the TNF homology domain (THD) of human and
murine CD134L (OX40L) can be produced in soluble forms that retain full receptor-binding
activity(Bossen et al., 2006). In contrast, when the THD of feline CD134L (aa 52–183) was
expressed in mammalian cells as N-terminal FLAG and Fc-tagged proteins, feline CD134L
bound to neither feline nor human CD134, irrespective of the tag(Willett et al., 2007). As
expression of both feline and human CD134 was detected readily by anti-CD134 antibody, the
data suggested that the ligand binding capacity of feline CD134L was disrupted by expression
in soluble form(Willett et al., 2007) (previously we had shown that surface expressed fCD134L
bound soluble feline CD134(Willett et al., 2007)). The amino acid sequences of feline and
human CD134L were compared in order to assess the degree of sequence divergence and to
investigate the likely cause of the failure to bind CD134 (Fig. 1a). FCD134L and hCD134L
shared 69% amino acid identity and when the 3D-structure of feline CD134L and CD134 were
modelled using the SWISS-MODEL modelling server in “First Approach” mode(Schwede et
al., 2003;Peitsch, 1996), based on the published structure of the human CD134L:CD134
complex(Compaan and Hymowitz, 2006) (Fig. 1b), divergent residues were identified in the
region predicted to form the receptor-binding interface (Fig. 1a). The contact residues at the
binding interface were predicted to be derived from four
regions; 96NCDG99, 119YRKGRK124, 142HLAFKDK148 and 179GFC181. 96NCDG99 was
conserved between feline and human CD134L, thus we postulated that a chimeric human x
feline CD134L bearing residues 114–183 of feline CD134L may retain the ligand-binding
specificity of fCD134L but the stability of human CD134L when expressed in soluble form.
Two FLAG-tagged chimeras were prepared consisting of aa 52–113 of human CD134L with
aa 114–183 of feline CD134L (h/fCD134L) and, as a control, the converse chimera with aa
52–113 of feline CD134L and aa 114–183 of human CD134L. Binding of the chimeric ligands
was assessed in comparison with feline, human and murine CD134L on cells expressing feline
or human CD134 (Fig. 1c). While human CD134L bound specifically to human CD134-
expressing cells, murine CD134L bound to both feline and human CD134L-expressing cells,
consistent with the promiscuity of binding observed with mCD134L previously(Bossen et
al., 2006;Willett et al., 2007). In contrast, neither fCD134L nor the h/fCD134L and f/hCD134L
chimeric ligands bound to either receptor. Thus, expression of the receptor binding domain of
feline CD134L in the context of human CD134L was insufficient to generate a functional
soluble CD134L.
3.2. Restoration of ligand binding by enforced covalent trimerisation
Ligands of the TNF family are expressed at the cell surface as trimeric type II transmembrane
proteins that may then be cleaved to yield soluble trimeric forms(Bodmer et al., 2002). The
soluble trimers interact with three molecules of their respective receptors, triggering secondary
multimerisation into supramolecular clusters that are capable of transducing signals(Holler et
al., 2003;Henkler et al., 2005;Siegel et al., 2004). The loss of specific binding properties by
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TNF family ligands when expressed in a soluble form may be the result of inappropriate
aggregation, as has been observed previously with the related members of the TNF family
mFasL and mLIGHT(Bossen et al., 2006). In order to restore bioactivity to soluble feline
CD134L, novel CD134L expression constructs were generated into which synthetic
trimerisation domains from either the collagen domain of murine adiponectin/ACRP30
(ACRP, aa 18–111)(Holler et al., 2003) or chicken tenascin-C (TNC, aa 110–139) had been
inserted (Berg et al., 2007). ACRP:FasL assembles into hexamers (of two trimers) that trigger
Fasmediated apoptosis(Holler et al., 2003) while the trimerisation domain of tenascin conferred
receptor binding activity upon TRAIL and FasL (bioactivity required further cross-linking of
the bound TNC-FasL trimers) (Berg et al., 2007). Binding studies comparing murine and feline
FLAG-tagged ACRP-CD134L revealed that while the murine ligand retained full binding
activity, the ACRP trimerisation domain did not restore binding activity to the feline ligand
(data not shown). Accordingly, no further studies with the FLAG-ACRP-fCD134L were
undertaken. In contrast, the introduction of a TNC trimerisation domain into either the FLAG
or Fc-tagged fCD134L vectors generated soluble fCD134Ls capable of binding feline CD134
(Fig. 2c). Ligand binding was first assessed on MCC cells expressing fCD134 or hCD134
ectopically (in comparison with vector-only control cells). Fc-TNC-fCD134L bound to the
majority of MCC cells expressing feline CD134 (99.8%, mean fluorescence intensity(MFI)
=221) but only weakly to those expressing human CD134 (45.5%, MFI=9.9). Conversely, Fc-
TNC-hCD134L recognised 100% of human CD134-expressing cells (MFI=608) but showed
no reactivity with feline CD134 (0.4%). Fc-TNC-mCD134L bound both feline and human
CD134 with similar efficiency (99.8%, MFI=300 and 99.8%, MFI=367 respectively). No
binding of the Fc-TNC-mFasL control protein was detected on either cell line, confirming the
specificity of the CD134L:CD134 interactions. Thus the species-specificity of feline and
human CD134L binding to their respective receptors was replicated when the ligands were
expressed in soluble forms bearing TNC trimerisation domains. Binding of the Fc-TNC ligands
to native, endogenously expressed, feline CD134 was assessed using the IL2-dependent T cell
line MYA-1. MYA-1 cells are non-transformed feline CD4+ T cells(Miyazawa et al., 1989)
and in cell culture the population is comprised of a mixture of cells at various stages of
blastogenesis. Thus CD134 expression can vary between analyses but is essentially bi-modal
(Willett et al., 2007) with larger blast cells being 100% CD134-positive, consistent with CD134
being up-regulated upon activation(Willett et al., 2007). Anti-feline CD134 mAb 7D6
recognised 83.3% of MYA-1 cells (MFI=19) (Fig. 2c). In comparison, Fc-TNC-fCD134L and
Fc-TNC-mCD134L bound to 82.4% (MFI=14) and 78.2% (MFI=7) of MYA-1 cells
respectively. The bi-modal expression pattern observed with anti-CD134 mAb was reproduced
by the soluble feline and murine Fc-TNC ligands, confirming sensitivity and specificity. In
contrast, Fc-TNC-hCD134L did not bind to MYA-1 T cells (0.5%).
The biochemical properties of the Fc-TNC ligands were confirmed by polyacrylamide gel
electrophoresis (PAGE). Under reducing conditions, the ligands migrated as a single dominant
species with an apparent molecular mass of ~50–60kDa, consistent with the predicted
molecular masses of 48,333, 50,237 and 48,986 for the feline, murine and human monomeric
ligands respectively (Fig 3b). Fc-TNC-hCD134L displayed a greater apparent size, this likely
due to the presence of 5 predicted sites for N-linked glycosylation (compared with 4 and 2 in
the feline and murine ligands respectively). Under non-reducing conditions, the ligands
migrated primarily at ~100–130 kDa, consistent with dimeric forms of the ligand driven by
dimerisation of the Fc-domain. However higher molecular weight forms of ~420 kDa were
also evident (Fig. 2b) as would be predicted for the hexameric form of the ligand due to covalent
trimerisation mediated by the TNC domain. This high molecular weight form was most evident
under native PAGE where the dominant species migrated at ~590kDa (feline and murine) and
~600kDa (human). Recent studies using a trimerizing isoleucine zipper (ILZ) domain to
stabilise human CD134L found that a hexamer with predicted molecular weight of 240kDa
and confirmed size of 336kDa (sedimentation analysis) eluted at ~540kDa using molecular
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sieve chromatography. It is likely that such discrepancies are the result of sizing estimates
being made between globular size standards and asymmetrical/non-globular species(Morris
et al., 2007). Here, although the hexameric form of Fc-TNC-fCD134L dominated, there was
also evidence of both smaller forms (dimer and trimer/tetramer) and single larger form ~940–
980kDa (dodecamer).
Given the similar binding profiles of Fc-TNC-fCD134L and anti-CD134 on IL2-dependent T
cells, the binding specificity of the Fc-TNC-fCD134L was confirmed on primary lymph node
CD4+ T cells (CD134 expression is restricted predominantly to CD4+ T cells in blood and
lymphoid tissues(Willett et al., 2007)). Anti-CD134 antibody stained 5.2% of CD4+ T cells
while Fc-TNC-fCD134L labelled 6.6% of CD4+ T cells (the difference of 0.8% corresponding
to the non-specific binding of Fc-TNC-hCD134L) (Fig. 3). Thus, Fc-TNC-CD134L and anti-
CD134 appear to identify similar populations of cells on primary CD4+ T cells, underlining
the potential for the use of Fc-TNC-ligands to assess receptor expression where monoclonal
antibodies are not available.
Introduction of the TNC trimerisation domain into the FLAG-CD134L construct restored
functionality to the soluble fCD134L (Fig. 4), the resulting protein binding selectively to feline
CD134 (66.2%, MFI=5) but not human CD134. However, binding was weak in comparison
with FLAG-mCD134L which recognised 99.7% (MFI=309) and 99.2% (MFI=291) of cells
expressing feline and human CD134 respectively. The weak binding of the FLAG-TNC-
fCD134L was confirmed on MYA-1 cells where 44.9% (MFI=3) of cells were stained while
FLAG-mCD134L recognised 86.5% (MFI=12), consistent with the binding patterns of mAb
7D6 and the Fc-TNC ligands. Given the poor binding of the FLAG-TNC-CD134L, subsequent
studies focussed on the Fc-TNC ligands.
3.3. Modulation of FIV infection by soluble feline CD134L
Soluble murine CD134L inhibited FIV infection of MYA-1 cells with the PPR and B2542
strains but had little effect on infection with strains such as GL8 and CPG41(Willett et al.,
2007). The effect of the Fc-TNC-CD134L ligands on infection with viruses at extremes of
sensitivity to murine CD134L was examined on MYA-1 cells (MYA-1 cells are IL2-dependent
T cells expressing low, but biologically relevant, levels of CD134 and CXCR4). Infection of
MYA-1 cells with B2542 and PPR was markedly reduced in a dose dependent manner by both
the feline (Fig. 5a., e.) and murine (Fig. 5b., f.) Fc-TNC ligands, significant inhibitory activity
being revealed with ligand concentrations as low as 0.1μg/ml (2nM). Fc-TNC-hCD134L had
no activity (not shown), consistent with the species-specificity of the CD134L:CD134
interaction. GL8 and CPG41 pseudotypes were more resistant to inhibition by the Fc-TNC
ligands compared to B2542 and PPR pseudotypes, significant inhibitory activity not being
revealed until a concentration of 12.5μg/ml (250nM) had been achieved. The reduction in PPR
and B2542 infectivity by both the Fc-TNC-fCD134L and Fc-TNC-mCD134L at 0.1, 0.4 and
2.5μg/ml was significant (t-test, P<0.001) relative to either GL8 or CPG41 at the equivalent
concentrations. The data suggest that when assayed on IL2-dependent T cells, the presumed
primary target of the virus, Fc-TNC ligands display potent but strain-specific inhibitory
activity.
Next, the inhibitory activity of the ligands was examined on cells expressing high levels of
both CD134 and CXCR4, CLL-CD134 cells (Fig. 5c., d., g., h.). On these cells, a dose
dependent inhibition of all viral strains was observed. GL8, CPG41, PPR and B2542 were
inhibited with similar efficiency with the feline Fc-TNC ligand. PPR appeared more resistant
to murine CD134L on CLL cells, this may reflect PPRs previously described ability to utilise
high levels of CXCR4 (see Fig. 7a) for CD134-independent infection(de Parseval et al.,
2004c). Given that GL8 and CPG41 were more resistant to the inhibitory activity of the Fc-
TNC ligands on MYA-1 cells, the data suggest that GL8 and CPG41 may either bind to MYA-1
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cells with a higher affinity than CLL-CD134 cells, or have the capacity to utilise a distinct
entry pathway on MYA-1 cells that is relatively insensitive to perturbation by Fc-TNC
CD134L. Conversely, it is notable that with matched doses of input virus, PPR and B2542
pseudotypes gave higher values on CLL-CD134 compared to MYA-1 and that PRR was the
least sensitive pseudotype to antagonism by Fc-TNC CD134L on CLL-CD134 cells.
The strain specificity of the antiviral effect of the Fc-TNC-ligands translated from the inhibition
of viral entry to suppression of viral replication in vitro. MYA-1 T cells were infected with
chimaeric viruses derived from the GL8 molecular clone and bearing the GL8 (Fig. 6a, d),
B2542 (Fig. 6b, e) and CPG41 (Fig. 6c, f) env genes at either 1000 TCID50 (a–c) or 100
TCID50 (d–f). While neither the human, feline nor murine ligands altered the kinetics of
infection of MYA-1 cells with chimaeras bearing the GL8 or CPG41 envs, the feline and murine
TNC-ligands significantly suppressed viral replication with B2542 at 5 days post-infection
although this inhibitory effect was overwhelmed by 8 days post-infection (Fig. 6b). When the
MOI of the input virus was reduced (Fig. 6e), the inhibitory effect was more stark with feline
CD134L suppressing viral replication to the end point of the assay. Thus, infection with B2542,
the viral strain for which entry was blocked most efficiently on MYA-1 cells (Fig. 5e. & f.),
was inhibited in the assay for productive infection (Fig. 6c.), confirming the sensitivity of this
strain to antagonism by Fc-CD134-CD134L. These data may suggest that viral variants that
interact with CD134 in a manner similar to B2542 may be susceptible to suppression in vivo
by endogenously produced CD134L while viruses such as GL8 and CPG41 would be resistant
to antagonism by CD134L and would thus have a replicative advantage.
Previous studies have demonstrated that over-expression of human CXCR4 alone is sufficient
to facilitate entry mediated by the PPR Env(de Parseval et al., 2004c). Accordingly, where
CXCR4 is abundant, infection mediated by PPR may be more efficient (and resistant to
antagonism of CD134 binding). CXCR4 expression on CLL-CD134 (Fig. 7a.) and MYA-1
(Fig. 7g.) was examined by flow cytometry; 92.7% of CLL-CD134 compared with 3.7% of
MYA-1 were CXCR4-positive. Simultaneously, we infected CLL-CD134 (Fig. 7c., e.) and
MYA-1 (Fig. 7i., k.) with HIV(FIV) pseudotypes in the presence of increasing concentrations
of the CXCR4 antagonist AMD3100. Infection of MYA-1 cells, where CXCR4 is limiting,
was blocked efficiently by AMD3100 in a dose-dependent manner. In contrast, infection of
CLL-CD134 cells, where CXCR4 is abundant, was less sensitive to modulation by AMD3100
but all viruses did exhibit a dose-dependent reduction in infectivity. On both cellular substrates,
PPR and CPG41 were least sensitive to antagonism by AMD3100, suggesting that these viruses
may have a higher affinity for CXCR4. In contrast with the differential effect of the Fc-TNC-
CD134Ls, infection with all four viruses was blocked efficiently by soluble Fc-CD134 on either
or CLL-CD134 (7d., f.) MYA-1 (7j., l.). CPG41 alone displayed a lower sensitivity to inhibition
by Fc-CD134 on MYA-1 cells, perhaps indicating a higher affinity for CD134 than GL8, PPR
and B2542. However, the findings with Fc-CD134 are in marked contrast to those observed
with Fc-TNC-CD134L on MYA-1 cells (Fig. 5e., f.) where both GL8 and CPG41 displayed
significant resistance to inhibition.
4. Discussion
The aim of this study was to produce a functional soluble feline CD134L with which the role
of the virus-receptor interaction in the pathogenesis of AIDS in FIV infected cats could be
studied. Previously, it was observed that soluble feline CD134L was non-functional when
expressed in identical expression constructs to those used for the production of fully-functional
soluble murine and human CD134L(Willett et al., 2007), either as a FLAG-tagged monomer
or as an Fc-tagged dimer. Thus while the TNF homology domain of murine and human CD134L
is sufficient to drive trimerisation and receptor binding, this does not extend to feline CD134L.
Electrophoretic analyses suggested that soluble feline CD134L may have been forming into
WILLETT et al. Page 8
Mol Immunol. Author manuscript; available in PMC 2010 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
misfolded aggregates as had been observed previously with murine FasL(Berg et al., 2007).
We predicted that preparation of a chimeric feline/human CD134L in which the ligand binding
face of human CD134L was exchanged with that of feline CD134L would retain the binding
properties of feline CD134 and the stability of human CD134L. However, once again, both the
feline/human and human/feline ligands were non-functional. As CD134L engages CD134 as
a trimer(Compaan and Hymowitz, 2006), we introduced a hexamerising domain from
ACRP-30 (adiponectin) to bring together two CD134L trimers, an approach that has proved
successful in the generation of functional CD95L(Holler et al., 2003). Our rationale was that
assuming the TNF homology domain of fCD134L was driving trimerisation of the ligand, then
the additional ACRP-30 domain would facilitate dimerisation of two trimers to from a stable
ligand with higher binding avidity. However, while this approach generated a functional murine
CD134L it did not restore receptor-binding activity to feline CD134L. We next examined the
trimerisation domain of tenascin-C, postulating that the spatial fixation of the TNF homology
domain may be critical missing element for receptor binding(Berg et al., 2007) and that the
ACRP-30 domain may not have recapitulated the arrangement of the trimer found in the native
membrane-bound form of CD134L that we had shown previously to bind CD134 well(Willett
et al., 2007). TNC-fCD134L fusion proteins tagged with either immunoglobulin (Ig) Fc or
FLAG were functional and bound feline CD134. Further, ligand binding specificity was
retained in the TNC-ligands in that both feline and human CD134L bound their respective
receptors specifically. The specificity and sensitivity of feline Fc-TNC-CD134L for CD134
mirrored that of the anti-CD134 MAb 7D6(Willett et al., 2007) staining IL2-dependent feline
T cells with similar intensity. Electrophoretic analyses indicated that the predominant form of
the native Fc-TNC-ligands was likely to be a hexamer; each monomer dimerising through the
Fc-tag and then trimerising through TNC domain (thus the Fc-TNC ligands would comprise
two ligand trimers and three Fc dimers). That soluble feline CD134L required the introduction
of a TNC domain suggests that the spatial distribution of the CD134L monomers is critical for
the correct presentation of the receptor binding face to CD134. Soluble CD134L is likely
trimeric however in the absence of the “stalk” region, the receptor binding residues may be
misaligned. Adding the TNC domain may fix the receptor-binding region in a spatial
distribution closer to the native membrane anchored-ligand, however this arrangement is still
sub-optimal (given the relatively modest increase in binding observed with the FLAG-tagged
ligand). Addition of the Fc domain would appear to increase the receptor binding affinity of
the TNC-CD134L fusion further, presumably by increasing avidity for CD134.
Whether cleavage of the membrane bound form in vivo releases a bioactive soluble mediator
will be of importance to the regulation of T cell survival during antigen-specific immune
responses. Elevated levels of soluble CD134L have been detected in the sera of patients with
Graves’ disease(Wang et al., 2006), suggesting a possible role in the immune-dysregulation
associated with this autoimmune response. Therefore, if the FIV Env protein competes with
CD134L for binding to CD134, either as a competitive antagonist or as a surrogate agonist,
then FIV infection may also modulate T cell survival indirectly.
The activity of the Fc-TNC-ligands as antagonists of FIV infection was investigated on primary
(non-transformed) IL2-dependent T cells (MYA-1) and on a cell line engineered to express
high levels of CD134 (CLL-CD134). Feline and murine Fc-TNC-CD134L had similar
activities against HIV(FIV) pseudotypes in assays of viral entry, inhibiting infection with the
B2542 and PPR strains by 60 and 40% respectively at a concentration of 0.1μg/ml (2nM). The
difference in sensitivity to inhibition between B2542/PPR and GL8/CPG41 was striking, GL8
and CPG41 requiring a ligand concentration of 12.5μg/ml (250nM) to achieve significant
inhibition of viral entry. However, when the assays were repeated on a cellular substrate on
which CD134 was expressed (ectopically) at high levels, the differential effect disappeared,
suggesting that the differential sensitivity that we observed may be dependent on the level of
CD134 expression. However, it is possible that the IL2-dependent T cells, express
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(endogenous) CD134 in a different conformation to that on CLL-CD134 cells and that the GL8
and CPG41 Envs are capable of recognising this endogenously expressed CD134 conformation
with a high affinity. It is notable therefore that infection with both the GL8 and CPG41 strains
was highly sensitive to perturbations of CRD2(Willett et al., 2006a), the region of CD134 that
forms a component of the CD134L binding site(Willett et al., 2006b;Willett et al., 2006a).
Previously, we hypothesised that GL8 and CPG41 may represent early isolates of FIV and that
such viral strains may target cell types efficiently where CD134 is limiting. With time post-
infection, and with developing immunodeficiency, viruses may acquire mutations that enable
a higher affinity interaction with the co-receptor CXCR4, evolving towards CD134-
independence. However, when sensitivity to the CXCR4 antagonist AMD3100 was compared,
the PPR and CPG41 strains were most resistant to inhibition, suggesting a higher affinity
interaction with CXCR4. The PPR strain is known to use CXCR4 efficiently, to the extent that
over-expression of CXCR4 alone can confer susceptibility to PPR infection(de Parseval et
al., 2004c). That CPG41 also displayed a substantial resistance to AMD3100 indicates that
sensitivities to CXCR4 and CD134 antagonism are not mutually exclusive. Our findings are
reminiscent of previous studies comparing infection of primary macrophages with cell culture
adapted and primary X4 strains of HIV where efficiency of infection was governed largely by
differential requirements for expression CD4 and/or CXCR4(Tokunaga et al., 2001). While
the previous study compared cell culture adapted with primary X4 strains of virus, here, we
compare four distinct primary strains of FIV (all CXCR4-dependent) and show that they differ
in their requirements for CD134 and CXCR4.
The efficiency of CD134 and CXCR4 usage may alter with time post infection; early in
infection viruses may dominate that have a high affinity for CD134 and either a high or low
affinity for CXCR4. As the CXCR4 binding site is concealed from potentially neutralising
antibodies, the affinity for CXCR4 may be less critical in early infection. With time post-
infection, as the neutralising antibody response diminishes, the affinity of the interaction with
CD134 may decline, leading to the emergence of CD134-independent viruses that are capable
of spreading into compartments rich in CXCR4-expressing cells. Thus, although FIV does not
appear to switch chemokine receptor usage from CCR5 to CXCR4 with disease progression
as has been described in HIV infection(Connor et al., 1997) (there are no data at present
supporting a role for chemokine receptors other than CXCR4 in FIV infection), by modulating
affinity for CD134 binding and a gradual progression towards usage of CXCR4 alone, the virus
may evolve in a similar manner. Accordingly, “late” viruses may be more sensitive to virus
neutralising antibodies and less transmissible due to their low affinity for CD134. Soluble
CD134L produced in vivo may suppress both the replication and spread of such variants. Thus,
viruses such as CPGammer(Diehl et al., 1995;de Rozieres et al., 2004) (a virus isolated
following acute phase passage(Diehl et al., 1995)) and GL8 (isolated from a cat displaying no
clinical signs of infection at the time of sampling) may represent the most robust (and
biologically relevant) challenge strains for FIV vaccine studies. If candidate vaccines can be
designed that protect against experimental challenge with these viruses, then it is likely that
they will protect cats in the field.
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Fig. 1.
Binding properties of chimeric CD134L fusion proteins. (A) The amino acid sequences of
feline and human CD134L were compared and regions of homology (dark shading) identified.
Start of the TNF homology domain (THD) and chimera junction are arrowed. Residues
predicted to lie at the CD134 binding face of CD134L are in blue boxes while aa F180, critical
for the CD134:CD134L interaction(Compaan and Hymowitz, 2006) is circled. (B) Predicted
3D-structure of the feline CD134L (blue) and CD134 (gray) complex illustrating residues at
the binding face of CD134L (dark blue) and residue F180(Compaan and Hymowitz, 2006)
(arrowed). (C) Binding of FLAG-tagged fCD134L, hCD134L, mCD134L and the human/
feline and feline/human chimeric CD134Ls (h/fCD134L and f/hCD134L) to MCC cells
expressing feline or human CD134. Bound ligands were detected with anti-FLAG followed
by PE-anti-mouse IgG. Cells were processed for flow cytometry and histograms represent
10,000 events collected in LIST mode, bars illustrate percentage positive. Histograms are
representative of two independent analyses.
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Fig. 2.
Enforced trimerisation of feline CD134L rescues ligand-specific binding. (A) Predicted
hexameric structure of the Fc-TNC ligands, comprising three IgG Fc dimers and two CD134L
trimers. (B) Polyacrylamide gel electrophoretic analyses of the Fc-TNA-ligands on reducing
SDS-PAGE, non-reducing SDS-PAGE or blue NativePAGE™. 1-Feline, 2-Murine, 3- Human;
m-monomer, d-dimer, t-tetramer, h-hexamer, dd-dodecamer (C) Binding of Fc-TNC ligands
to MCC cells expressing feline or human CD134 (or vector only control), or to MYA-1 cells.
Fc-TNC-fCD134 was compared with Fc-TNC-mCD134, Fc-TNC-hCD134 or Fc-TNC-
mFasL. Bound ligands were detected with phycoerythrin (PE)-conjugated anti-IgG Fc. CD134
expression was assessed using mAb 7D6, bound antibody being detected with PE-anti-mouse
IgG. Cells were processed for flow cytometry and histograms represent 10,000 events collected
in LIST mode, bars illustrate percentage positive. Histograms are representative of two
independent analyses.
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Fig. 3.
Binding of anti-CD134 and Fc-TNC-CD134L to primary CD4+ T cells. Popliteal lymph node
cells were stained with Fc-TNC-fCD134L, anti-CD134 and as a control for non-specific
binding, Fc-TNC-hCD134. Bound ligands were detected with phycoerythrin (PE)-conjugated
anti- human IgG Fc. CD134 expression was assessed using mAb 7D6, bound antibody being
detected with PE-anti-mouse IgG. Cells were processed for flow cytometry and dotplots
represent 10,000 events collected in LIST mode and analysis gates show percentages of total
cells analysed. Dotplots are representative of two independent analyses.
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Fig. 4.
Specific binding of FLAG-tagged TNC feline CD134L to feline CD134. Specificity of binding
of FLAG-tagged TNC feline CD134L was examined on MCC cells expressing human or feline
CD134, vector only control cells (control), or MYA-1 T cells. Binding was compared with
FLAG-tagged murine CD134L. Bound ligands were detected with anti-FLAG followed by PE-
anti-mouse IgG. Cells were processed for flow cytometry and histograms represent 10,000
events collected in LIST mode, bars illustrate percentage positive. Histograms are
representative of two independent analyses.
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Fig. 5.
Strain-specific inhibition of viral entry by Fc-TNC ligands. Inhibitory activities of Fc-TNC-
fCD134L (A, C, E, G) and Fc-TNC-mCD134L (B, D, F, H) were compared on MYA-1 T cells
(A, B, E, F) and CLL-CD134 (C, D, G, H) against HV(FIV) pseudotypes bearing GL8, B2542,
PPR and CPG41 Envs. (A–D) Luciferase activity versus Fc-TNC-CD134L concentration, (E–
H) Infectivity (percent infection relative to no antagonist) versus Fc-TNC-CD134L
concentration. Each point represents the mean +/− standard error (n=3).
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Fig. 6.
Effect of Fc-TNC-CD134L on productive infection. MYA-1 cells were infected with 1000 (A–
C) or 100 (D–F) TCID50 of GL8 chimaeras bearing the (A, D) GL8, (B, E) B2542 and (C, F)
CPG41 envs in the presence of 12.5μg/ml Fc-TNC-CD134L (mouse, human, or feline) or saline
control. Cultures were maintained for one week and supernatants analysed for virus production
by non-isotopic reverse transcriptase assay (Absorbance 405nm). Infection with B2542 was
inhibited with the murine and feline but not human ligands. Results are mean of two replicates
and are typical of two analyses.
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Fig. 7.
Strain-specificity of receptor antagonism. CXCR4 (A., G.) and CD134 (B., H.) were quantified
on CLL-CD134 (A., B) and MYA-1 (G., H.) cells by flow cytometry. Bound anti-CXCR4
antibody was detected with PE-anti-mouse IgG. Histograms show 10,000 events collected in
LIST mode. Inhibitory activity of AMD3100 (C., E., I., K) and soluble Fc-CD134 (D., F., J.,
L.) were then compared on CLL-CD134 (C., D., E., F.) and MYA-1 (I., J., K., L.) cells. (C.,
D., I., J.) Luciferase activity versus antagonist concentration, (E., F., K., L.) Infectivity (percent
infection relative to no antagonist) versus antagonist concentration. Each point represent the
mean +/− standard error (n=3).
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